Product Description
Niclosamide is an anthelmintic drug that has been used for over 50 years mainly to treat tapeworm infections. However, with the increase in drug repurposing initiatives, niclosamide has emerged as a true hit in many screens against various diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29603892/)
Mechanisms of Action: STAT3 Inhibitor,mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | India | Italy | Korea | Lebanon | Luxembourg | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Portugal | Russia | Sweden | Taiwan | Thailand | Turkey | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: UNION therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Proctitis
Phase 1: Healthy Volunteers|Prostate Cancer|Zika Virus Infection
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TFF-N1-001 | P1 |
Completed |
Healthy Volunteers |
2022-01-26 |
28% |
| UCDCC#264 | P1 |
Completed |
Prostate Cancer |
2022-01-14 |
|
| ND | P2 |
Active, not recruiting |
Proctitis |
2019-03-07 |
|
| AWP MDFF | P1 |
Not yet recruiting |
Zika Virus Infection |
None |